Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00786175
Other study ID # CRE-2008.336
Secondary ID
Status Withdrawn
Phase N/A
First received November 5, 2008
Last updated August 21, 2015
Start date October 2008
Est. completion date December 2018

Study information

Verified date August 2015
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Ethics Committee
Study type Observational

Clinical Trial Summary

Hypothesis: there is a high prevalence rate of diabetes, including asymptomatic undiagnosed glucose intolerance, among subjects with coronary heart disease in Hong Kong.

A cross-sectional survey is planned to study the rate of undiagnosed diabetes and glucose intolerance among the Chinese patients with coronary heart disease in Hong Kong. The survey results will be important for us to plan the logistics to investigate and manage the potential glucose abnormality of our heart disease patient.


Description:

Diabetes is becoming an epidemic in Hong Kong, affecting over 10% of population and causing a major burden to the health care system. Over 30-40% of patients admitted to the medical wards of the Hospital Authority hospitals have diabetes as a contributory factor. It was estimated that thirty to fifty percent of patients with stroke, heart failure or acute myocardial infarction have diabetes as a key causative factor. However, the exact prevalence rate of diabetes, including asymptomatic undiagnosed glucose intolerance, among subjects with coronary heart disease is still unknown in Hong Kong. Many heart disease patients with undiagnosed diabetes remained being untreated on their abnormal glycemic status, which will further aggravate the heart disease and impair the prognosis.

The investigators plan to conduct a cross-sectional survey to study the rate of undiagnosed diabetes and glucose intolerance among the Chinese patients with coronary heart disease in Hong Kong. The survey results will be important for us to plan the logistics to investigate and manage the potential glucose abnormality of our heart disease patient.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients aged 18 years

2. Subjects admitted to Hospital Authority hospital as in-patients (AHNH) with the diagnosis of coronary heart disease (ICD code 410-414) during the period 1 April 2007 to 31 March 2008.

3. Subjects admitted to AHNH for the procedure Percutaneous Coronary Intervention (PCI) to manage coronary heart disease.

Exclusion Criteria:

1. Known Type 1 diabetes defined as history of ketosis [acute symptoms with heavy ketonuria (>3+) or ketoacidosis] or heavy ketonuria (3+) or continuous requirement of insulin treatment within one year of diagnosis and thereafter.

2. Patients with terminal malignancy or other life-threatening diseases with less than 6-month expected survival

3. Patients with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Locations

Country Name City State
China Hong Kong Institute of Diabetes and Obesity Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

China, 

See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A